Limitations, agreements, and source contact

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · Source last updated 2024-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

point Of Contact

email

info@sellaslife.com

organization

Sellas Life Sciences

phone

646-200-5278

title

Dr Dragan Cicic, Chief Development Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice